Human Pharmacokinetic Study of Heated Intraperitoneal Oxaliplatin in Increasingly Hypotonic Solutions after Complete Resection of Peritoneal Carcinomatosis

Purpose: We studied the pharmacokinetics of heated intraoperative intraperitoneal (i.p.) oxaliplatin (LOHP) solution and its safety profile in increasingly hypotonic solutions. This is the first clinical study of i.p. chemohyperthermia with hypotonic solutions. Methods: Patients with peritoneal carcinomatosis (PC) underwent complete cytoreductive surgery followed by intraoperative i.p. chemohyperthermia (IPCH) with successive dextrose solutions of 300, 200, 150 and 100 mosm/l. LOHP (460 mg/m2) was administered in 2 liters of solution/m2 at an i.p. temperature of 42–44°C for 30 min. IPCH was performed using an open procedure (skin pulled upwards) with a continuous closed circuit. Patients received intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2) just before IPCH to maximize the effect of LOHP. i.p. plasma and tissue samples were analyzed by means of atomic absorption spectrophotometry. Sixteen consecutive patients with PC of either gastrointestinal or peritoneal origin were treated. The safety of the procedure was studied. Results: Pharmacokinetics: The mean duration of the entire procedure was 7.7 ± 2.6 h. Half the LOHP dose was absorbed within 30 min at all dose levels. Absorption was not higher with hypotonic solutions than with isotonic solutions. The area under the curve of LOHP in plasma did not increase with decreasing osmolarity of the i.p. solutions. Intratumoral LOHP penetration was high; it was similar to that at the peritoneal surface, and about 18 times higher than that in nonbathed tissues. LOHP penetration was not significantly increased by using hypotonic solutions. Safety: There was a very high incidence of unexplained postoperative peritoneal bleeding (50%) and unusually severe thrombocytopenia in the 150 and 100 mosm/l groups. Conclusion: Contrary to experimental studies, this clinical study showed no increase in tumoral or systemic penetration of LOHP with i.p. hypotonic solutions (200, 150 or 100 mosm/l) during IPCH. A high incidence of i.p. hemorrhage and thrombocytopenia was observed.

[1]  I. Miyazaki,et al.  Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study , 2004, World Journal of Surgery.

[2]  P. Sugarbaker Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[3]  J. Pignon,et al.  Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Ducreux,et al.  Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy , 2001, Cancer.

[5]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Pattyn,et al.  Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra‐abdominal cancer , 2000, The British journal of surgery.

[7]  D. Elias,et al.  Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. , 2000, International journal of surgical investigation.

[8]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Tsujitani,et al.  Administration in a Hypotonic Solution Is Preferable to Dose Escalation in Intraperitoneal Cisplatin Chemotherapy for Peritoneal Carcinomatosis in Rats , 1999, Oncology.

[10]  M. Ychou,et al.  Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Sugarbaker Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. , 1998, Seminars in surgical oncology.

[12]  D. Elias,et al.  [Tumor implantation in cicatrization sites following surgery for digestive cancers]. , 1996, Journal de chirurgie.

[13]  Takuma Sasaki,et al.  Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. , 1996, Surgery.

[14]  F. Zoetmulder Cancer cell seeding during abdominal surgery: experimental studies. , 1996, Cancer treatment and research.

[15]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[16]  B. Debaene,et al.  Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. , 1994, Hepato-gastroenterology.

[17]  Y. Ichinose,et al.  Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results. , 1993, The Journal of thoracic and cardiovascular surgery.

[18]  K. Kobayashi,et al.  Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. , 1990, Annals of surgery.

[19]  J. Mcvie,et al.  Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. , 1989, Cancer research.

[20]  E. Smith,et al.  The effect of reduced osmolarity on platinum drug toxicity. , 1989, British Journal of Cancer.

[21]  Y. Osaki,et al.  Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. , 1984, Cancer research.